Brooker Consulting is proud to partner with Neuroscience Trials Australia to recruit a Head of Clinical Operations and Chief Operating Officer.
Neuroscience Trials Australia Pty Ltd (NTA) is an Australian-based, niche, contract research organisation (CRO) specialising in neuroscience and other therapeutic areas.
NTA delivers high-quality, full-service tailored
solutions, supporting Phase I to IV trials.
Experience
NTA's expertise include epilepsy, stroke and stroke-related conditions, multiple sclerosis, Alzheimer’s
disease/cognitive diseases, mental health, ALS/MND, Parkinson’s disease, spinal cord injuries, Huntington’s disease, neurosurgery, pain, ophthalmology neuromuscular disease and migraine, rare and paediatric disease, and first-in-human Phase I studies.
NTA is increasingly working on several trials across other therapeutic indications including, but not limited to oncology, immunology, devices and diabetes to support their clients’ portfolios.
Global Reach
NTA is one of the few CRO’s globally that specialises in CNS projects. NTA supports pharmaceutical,
biotechnology, cell therapy and device companies to undertake their clinical trials according to global
regulatory standards, including the TGA, FDA and EMA.
NTA has global strategic partnerships to tailor their clients’ clinical trial programs.
Furthermore, NTA has direct access to therapeutic disease specialists, key opinion leaders and clinical trial
expertise that collectively enable NTA to deliver quality clinical trial services to valued clients.
What Matters to NTA?
Values
Innovation and excellence
Commitment and passion
Integrity and rigour
Collaboration and teamwork
Established in 2001, NTA’s primary aim was to build a world-class service capability for clinical trials within the
Florey. It is now a highly respected CRO playing a key role in the translation of research and development, into
clinical practice which directly enhances health outcomes.
NTA continues to support the neuroscience clinical ecosystem by redirecting funding back to neuroscience
research undertaken at The Florey. The Florey is the largest brain research centre in the southern hemisphere
and one of the largest independent medical research institutes in Australia.
Meet the Team
Dr Irene Kourtis,
Chief Executive Officer
GAICD, PhD, GDipIPLaw
Dr Kourtis is a highly regarded leader having built a career within life science and service industries supporting diagnostics, medical research, genomics, and forensic medicine for improved clinical outcomes. Dr Kourtis has board and executive level experience across NFP, government and private sectors.
With experience in innovation with technology, Irene is successful in building organisational capability to deliver quality, contract services across biomedical, biotechnology, and pharma sectors. Irene has a track record of establishing world class infrastructure and supporting the translation of R&D into clinical application. Having led several ‘growth through transformation strategies’, Irene is skilled in creating and securing business opportunities. Qualified with a PhD in Virology and post-doctoral research in the use of gene therapy applications against glioblastomas at the Department of Surgery, the University of Melbourne, Royal Melbourne Hospital. This is complemented with a Graduate Diploma in Intellectual Property Law and a graduate of the Australian Institute of Company directors. Irene looks forwarding to working with NTA’s partners and forging new collaborations into the future.
Prof Steven Petrou
Florey Director
PhD FAHMS
Professor Petrou is a PhD trained neuroscientist who focuses on the biology of disease and therapy development in neurogenetic disorders. Professor Petrou’s rigorous approach to his research, and his ability to translate this research into commercial outcomes is the result of his focus on interdisciplinary research. His laboratory successfully amalgamates physics, engineering, computation, cell and molecular biology, genetics, neurobiology and clinical research to improve the lives of patients with neurogenetic diseases. As a leader in the area of precision medicine in epilepsy he has published key papers that not only describe novel disease mechanisms but also identify a number of treatment modalities including repurposing of existing drugs, novel small molecule development and gene therapy. He collaborates nationally and internationally with leading clinicians and scientists and has co-founded two biotech companies to commercially develop new treatments for patients with epilepsy and related disorders. Professor Petrou has been the Deputy Director of the Florey since 2012 and the Head of a successful laboratory which has enjoyed continuous funding for the past 20 years. He is also a current NHMRC Principal Research Fellow.
About the Roles
Reporting to the CEO, you will drive the transition of NTA’s business, currently operating from within The Florey, into the NTA Company, which has recently commenced operating. Through inspirational leadership, collaboration, and energy, you will work in partnership with the Executive team and CEO, to deliver NTA’s new strategic direction.
As part of this endeavour, the NTA Executive and both of these roles, will continue to work closely with The Florey, and build NTA capability and grow our commercial operations.
